FDA recall: "fat burner" supplement found laced with antidepressant and banned industrial chemical

A Florida company has issued a nationwide voluntary recall of a weight-loss supplement after federal laboratory testing found it secretly contained a prescription antidepressant and a toxic industrial chemical that has caused deaths in bodybuilders and dieters who bought it online. The recall, filed by Ana Salazar Modela Tu Cuerpo Inc. of Davie, Florida, and posted to the Food and Drug Administration's recall database on August 31, covers a single lot of Lipofit Extreme Fat Burner 2.0, an over-the-counter product sold directly to consumers through online orders.

The product is packaged as a two-part regimen: a daytime (AM) tablet and a nighttime (PM) tablet, marketed together as a fat-burning system. According to the company's recall notice, FDA laboratory analysis found the AM tablets contained undeclared fluoxetine, the active ingredient in the prescription antidepressant sold under brand names including Prozac, while the PM tablets contained undeclared 2,4-dinitrophenol, commonly known as DNP, an industrial chemical never approved for any use in the human body.

What the testing found

Fluoxetine is a legitimate, FDA-approved medication when prescribed and monitored by a physician for depression, bulimia and obsessive-compulsive disorder, but it carries risks including suicidal thoughts, abnormal bleeding, seizures and dangerous interactions with other drugs when taken without medical supervision. DNP is a different category of hazard altogether. It was originally developed as an industrial dye, wood preservative, herbicide and pesticide, and briefly marketed as a weight-loss aid in the 1930s before the FDA banned it for human consumption in 1938 after it caused blindness, organ failure and death in users.

The recall notice states plainly that "products containing fluoxetine and DNP cannot be marketed as dietary supplements," and warns that combined, the two undeclared ingredients "can cause a wide range of serious and potentially life-threatening adverse effects," including nausea, vomiting, sweating, dizziness and headaches in the short term, and dangerous heart rhythm problems, rapid heart rate, cardiac arrest, seizures and suicidal ideation with continued use. The company said it has not received any reports of adverse events tied to the recalled lot as of the recall date.

Scope of the recall

The recalled lot is identified as Lot 25M12F, with an expiration date of September 2027. The product was sold in the United States exclusively through online orders directly to individual consumers, meaning there is no retail chain or distributor list to check — anyone who purchased the product from the company's website or affiliated online storefronts within the product's shelf life is considered potentially affected. The recall notice instructs consumers who have the product to stop using it immediately, keep it away from children and other household members, and refrain from selling, giving away or otherwise transferring it to anyone else while they await return instructions from the company.

• Product: Lipofit Extreme Fat Burner 2.0 (AM/PM tablet system)
• Lot number: 25M12F, expiration 09/2027
• Hazard: undeclared fluoxetine (AM) and undeclared DNP (PM)
• Distribution: direct-to-consumer online sales only, nationwide
• Adverse events reported to date: none, per the company

A warning that predates the recall

The recall did not come out of nowhere. The FDA had already flagged the same product in a medication health fraud notification published in June, warning consumers against buying or using Lipofit Extreme 2.0 after the same laboratory analysis identified the hidden fluoxetine and DNP. That notice described DNP toxicity as capable of producing "dangerously high body temperature, rapid heart rate and breathing, cardiac arrest and death," and noted that long-term exposure can damage the eyes, skin, bone marrow, nervous system and heart. The gap of roughly two months between the initial public warning and the formal recall action reflects how the FDA's health fraud alerts and product recalls move on separate tracks: the agency can warn consumers about a dangerous product immediately after testing, while a recall — which obligates the seller to notify purchasers and arrange returns — depends on the company's cooperation or, absent that, further enforcement action.

DNP's danger is not theoretical or new. The chemical has a documented history of killing people who buy it as a weight-loss aid, mostly through unregulated online sellers. In one federal case highlighted in Justice Department and FDA enforcement records, a retired New Jersey physician was sentenced to prison for selling DNP online between 2017 and 2019; prosecutors presented evidence that a customer in the United Kingdom died of DNP toxicity after taking pills purchased from him, and that he knew the chemical was toxic and illegal to market as a drug. The same defendant later pleaded guilty to obstruction of justice after fabricating a cancer diagnosis in an attempt to delay his trial.

"Products containing fluoxetine and DNP cannot be marketed as dietary supplements," the FDA-published recall notice states, adding that DNP "is not FDA approved for any use."

Part of a broader problem with tainted supplements

The Lipofit case fits a pattern the FDA has tracked for years through its ongoing scrutiny of the weight-loss supplement market. In agency guidance on contaminated weight-loss products, the FDA explains that it periodically tests products marketed as "natural" or "herbal" weight-loss aids and repeatedly finds them spiked with active pharmaceutical ingredients — sometimes prescription drugs, sometimes banned substances like DNP or sibutramine, a weight-loss drug pulled from the U.S. market in 2010 over cardiovascular risks. Because these products are sold as dietary supplements rather than drugs, they do not go through the FDA's premarket approval process, and problems typically surface only after the agency tests products already on the market or after consumers report harm.

Consumers researching weight-loss supplements have no reliable way to detect hidden pharmaceutical ingredients on their own; the substances do not appear on labels and cannot be identified by taste, smell or appearance. The FDA has repeatedly urged consumers to be skeptical of products promising rapid weight loss, especially those combining a "daytime" and "nighttime" formula, sold primarily through unaffiliated websites rather than established retailers, and lacking a listed U.S.-based manufacturer that can be independently verified.

What affected consumers should do

Anyone who purchased Lipofit Extreme Fat Burner 2.0 is advised to stop taking it immediately and contact the company for return instructions rather than discarding or passing it on. Consumers or their physicians who suspect they have experienced side effects after using the product, or any other tainted supplement, are directed to file a report through the FDA's MedWatch Voluntary Reporting Program, either online or by fax to 1-800-FDA-0178. Reports submitted through MedWatch help the agency track adverse events tied to a product and can support further enforcement action, including a formal product seizure or referral for criminal prosecution, if the company does not fully comply with the recall.

The recall notice does not indicate that the FDA has yet pursued the kind of criminal referral seen in the earlier DNP prosecution, and the agency's public statements to date describe this as a voluntary, company-initiated recall rather than a mandatory FDA order. Consumer safety attorneys and public health researchers who track supplement recalls note that voluntary recalls of unapproved, ingredient-tainted products often proceed slowly precisely because the sellers operate outside conventional retail and distribution channels, making full consumer notification difficult to verify.

What happens next

The FDA continues to list Lipofit Extreme Fat Burner 2.0 among its active recalls and health fraud notifications, and the agency's enforcement database will be updated if additional lots, related products from the same company, or adverse event reports surface. Because the product was sold only through direct online transactions, public health officials are relying on the recall notice itself, media coverage and the company's own outreach to reach purchasers, rather than a retail recall process with in-store signage. Consumers are advised to check the FDA's recall and safety alert pages periodically for updates on this and other supplement recalls, particularly given the agency's stated pattern of finding hidden pharmaceutical ingredients in weight-loss products marketed through similar online-only channels.